

TELMISARTAN

Class: Angiotensin II Receptor Blocker.

Indications: Cardiovascular risk reduction: Cardiovascular risk reduction in patients ≥ 55 years of age unable to take ACE inhibitors and who are at high risk of major cardiovascular events (eg, MI, stroke, death)

Hypertension: For the treatment of hypertension, alone or in combination with other antihypertensive agents

Available dosage form in the hospital: 40MG TAB, 80MG TAB

Dosage:

- **Hypertension:** Oral: Initial: 40 mg once daily; usual maintenance dose range: 20-80 mg daily. Patients with volume depletion should be initiated on the lower dosage with close supervision

- **Cardiovascular risk reduction:** Oral: 80 mg once daily. **Note:** It is unknown whether doses < 80 mg daily are associated with a reduction in risk of cardiovascular morbidity or mortality.

Renal Impairment :

No dosage adjustment necessary; hemodialysis patients are more susceptible to orthostatic hypotension

Hepatic Impairment:

Initiate therapy with low dose; titrate slowly and monitor closely.

Canadian labeling: Recommended initial dose: 40 mg daily

Common side effect:

Cardiovascular: Intermittent claudication (7%; placebo 6%), chest pain ($\geq 1\%$), hypertension ($\geq 1\%$), peripheral edema ($\geq 1\%$). Central nervous system: Dizziness ($\geq 1\%$), fatigue ($\geq 1\%$), headache ($\geq 1\%$), pain ($\geq 1\%$)

Dermatologic: Skin ulcer (3%; placebo 2%). Gastrointestinal: Diarrhea (3%), abdominal pain ($\geq 1\%$), dyspepsia ($\geq 1\%$), nausea ($\geq 1\%$). Genitourinary: Urinary tract infection ($\geq 1\%$). Neuromuscular & skeletal: Back pain (3%), myalgia ($\geq 1\%$)

Respiratory: Upper respiratory infection (7%), sinusitis (3%), cough ($\geq 1\%$), pharyngitis (1%)

Pregnancy Risk Factor: D